Overview
NeuBase Therapeutics, Inc., is accelerating the genetic revolution developing a new class of designer synthetic medicines. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by genetic diseases (remembering that every disease is genetic), including those that can only be treated through accessing of double-stranded DNA and RNA structures. Using PATrOL™ technology, NeuBase aims to first tackle genetic neurological disorders.